Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pembrolizumab in relapsed or refractory classical Hodgkin lymphoma
NL-OMON42797Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in classical Hodgkin lymphoma (cHL), sponsored by Merck & Co. Primary endpoints: Safety and tolerability of pembrolizumab and Overall Response Rate. Started Aug 2015; status: active, not recruiting.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NL-OMON42797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42797.